Chronix Biomedical Corporation is pioneering a breakthrough approach to the diagnosis and management of chronic diseases and cancer. A molecular diagnostic company, Chronix provides sequencing services to clinicians, universities, industry, and government agencies for breast cancer, prostate cancer, colorectal cancer, brain injuries and concussions, bovine spongiform encephalopathy (mad cow disease), and chronic fatigue syndrome. The firm has developed proprietary technology that measures and categorizes circulating nucleic acids, DNA sequences circulating in the blood that are associated with specific changes in disease and health status. Chronix plans to collaborate with a variety of partners to develop and market its DNA-based assays that have the potential to transform the management of a broad range of cancers and other conditions. Chronix is headquartered in San Jose, CA with research facilities in Germany.